Navigation Links
Signalife Announces Reverse Stock Split, Preferred Stock Dividend and $5 Million Investment
Date:9/10/2008

ho take a longer-view in holding the company's common shares. Management construes these as very positive developments, demonstrating our commitment to the technology and our confidence in the company's future, together with our commitment to eliminate the manipulation of our stock price to the detriment of our long-term shareholders."

Finally, we have received notice that numerous non-shareholders whose lives have been saved -- and others who cannot afford to travel to a screening event -- will be intervening in the current lawsuits and suing brokerage houses and co-conspiratorial lawyers for preventing them from obtaining potentially life-saving heart screenings. We do not know who will be representing these human beings and have no further knowledge related thereto.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. More information is located at http://www.signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknown risks, which may cause the companies' actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating the companies' technology procure market acceptance for these products, failure to obtain federal or
'/>"/>

SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Signalife Announces Anticipated Date of Transition to OTCBB
2. Signalife to Issue Breaking News Regarding Vianale & Vianale Tomorrow
3. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
4. AFL To Return to Oklahoma Due to Overwhelming Demand for Signalife Heart Screening
5. Signalife Board Approves Merger
6. Signalife Announces AFL Joins NIH Education Program
7. Signalife Appoints Lee Ehrlichman President and Chief Operating Officer
8. Signalife Appoints Lee Ehrlichman as Company Director and Operations Director; Additional Notice Received From Amex Regarding Sharholders Equity Deficiency
9. Signalife Awarded New U.S. Patent, System For, And Method Of, Monitoring Heartbeats Of A Patient
10. Signalife Announces Webcast
11. AMEX Notifies Signalife That It Has Accepted Signalifes Plan of Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... With the accelerated aging of the ... as well as the improved medical care facilities ... industry has been developing quickly, especially in vitro ... in vitro diagnostics market size reached RMB22.98 billion, ... diagnostic reagents. , Read complete report with ...
(Date:7/30/2014)... 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... 180 List of Outstanding Issues (LOI) from the European ... (CHMP) for the NB32 Marketing Authorization Application (MAA). NB32 ... investigational drug candidate being evaluated for weight loss. ... time point were adequately addressed by the Company based ...
(Date:7/30/2014)... July 30, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that their ... for the reduction of recurrence of hypertrophic ... been initiated. Logo - ...
(Date:7/30/2014)... Immunology Summit-2014 will be ... scientists in the field, which includes prominent personalities ... Western Reserve University School of Medicine, USA, who ... “The effects of recombinant human IL-6 and recombinant ... Biragyn, a Senior investigator at National Institute on ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... GREENWOOD VILLAGE, Colo., Dec. 22, 2011 Ampio Pharmaceuticals, ... or the "Company"), a company that discovers and develops ... entities ("NMEs"), today announced notification of the granting of ... METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM". ...
... Mich., Dec. 22, 2011  Neogen Corporation (NASDAQ: NEOG ... of FY 2012, which ended Nov. 30, increased 2.2% from ... the quarter was $5,237,000, or $0.22 per share, compared to ... $0.26 per share. Year-to-date revenues for the first ...
... 2011 Epitomics, Inc., a California based biotech ... a Star Program in collaboration with the University ... application of a new, advanced antibody assay technique, ... measurements of antibody-antigen interactions. Over the course of ...
Cached Biology Technology:Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™ 2Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™ 3Neogen Reports Second Quarter Results 2Neogen Reports Second Quarter Results 3Neogen Reports Second Quarter Results 4Neogen Reports Second Quarter Results 5Neogen Reports Second Quarter Results 6Epitomics, Inc. and University of California, Davis, Complete Star Program for High-Throughput Measurement of Antibody-Antigen Interactions 2
(Date:7/30/2014)... pieces is still in its infant stage. But it ... major significance. "Amazingly often, we are findingin addition to ... we found in Baltic amber," explained Bonn paleontologist Professor ... from the Baltic Sea region, which is almost 10,000 ... the coastal regions of Mecklenburg, Poland and Belarus. The ...
(Date:7/30/2014)... unveiled the first high-resolution map of the carbon ... of Per. The new and improved methodology used ... for future market-based carbon economies. The new ... diversity and it provides the critical input to ... land use, and enforcement purposes. The technique includes ...
(Date:7/29/2014)... Bristol,s Nutrition and Behaviour Unit (NBU) has looked into ... meals. , The research, to be presented at the ... 2014) in Seattle, USA this week [29 July to ... was led by Professor Jeff Brunstrom, and is based ... of a Biotechnology and Biological Sciences Research Council (BBSRC) ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... Los Angeles, London, New Delhi, Singapore and Washington DC (July ... be advertised directly to the patient, and the results of ... the future adoption of pharmacogenetic/genomic testing, according to a position ... be published in the August 2009 issue of the ...
... many couples conceive healthy children and is generally considered ... PGD in mice suggests that this procedure may increase ... PGD is used alongside assisted reproduction technologies ... disease (e.g. Ashkenazi Jews who have a high incidence ...
... the July issue of Biomaterials , published by ... report on the first lab-grown motor nerves that are ... human body. The model system will drastically improve ... diabetic neuropathy and later, possibly multiple sclerosis (MS). In ...
Cached Biology News:Genetic tests advertised directly to the consumer 2Preimplantation genetic diagnosis may pose neurological risks 2Researchers design first model motor nerve system that's insulated and organized like the human body 2
Applications: Western blotting ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
... Amplification Kit, 100 reactions. Prepare circular ... 4-6 h.Generate microgram quantities of template ... material.Use amplified DNA directly for cycle ... or M13 liquid cultures, colonies, plaques, ...
Biology Products: